BioCure Pharma's founder Dr. Youngman Oh has developed a number of novel inventions in the area of upper respiratory disease, as well as oncology, specifically Radiation Therapy-Induced Fibrosis (RTIF). BioCure Pharma's drug pipeline ranges from pre-clinical studies to Phase II trials. The intellectual property and patents held by BioCure and its subsidiaries, AltruGen and InflammoGen, present many additional opportunities in key areas such as cancer and diabetes. Biocure Pharma'a mission is to aggressively develop a new generation of drugs that will vastly improve the quality of life of people suffering from asthma-related diseases and post-operative radiation therapy. By addressing each underlying disease state, our technologies prevent and suppress, with a focus on safety and efficacy.
| Website | http://www.biocurepharma.com |
| Employees | View employees |
| Industry | Manufacturing General, Manufacturing |
| SIC | SIC Code 57 Companies, SIC Code 573 Companies |
| NAICS | NAICS Code 44 Companies, NAICS Code 449 Companies, NAICS Code 443 Companies |
Looking for a particular BioCure Pharma employee's phone or email?
BioCure Pharma Questions
The NAICS codes for BioCure Pharma are [44, 449, 443].
The SIC codes for BioCure Pharma are [57, 573].
